Biocon inks licensing pact with Biomm for diabetes management drug Semaglutide in BrazilMoneycontrol • 7 days ago
Under the agreement, Biocon will handle the development, manufacturing, and supply of the diabetes management drug, while Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Share to Feed
Net Sales are expected to increase by 3.5 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 3,730.4 crore, according to ICICI Securities.
The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November.
As part of the deal over 430 employees associated with the business are expected to transition to Eris
Biocon Share Price | In an another development, the company's subsidiary received observations from US Food and Drug Administration (USFDA).
The trigger for this inspection was a Pre-Approval Supplement (PAS) filed by BBL's customer late last year
Around 70% of stocks in Nifty MidCap 100 and Nifty SmallCap 100 indices witnessed a rise in mutual fund stakes in December 2023 quarter, according to Ace Equities data.
Ipca Laboratories saw a breakout of downward sloping resistance trendline adjoining highs of December 5 last year and January 12 this year. The stock formed strong bullish candlestick pattern on the daily charts with healthy volumes.
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 332 in its research report dated January 17, 2024.
Bandhan Bank has gained strength after consolidation in the recent past and went very close to the September swing high. The stock formed healthy bullish candlestick pattern on the daily timeframe with significantly higher volumes.